NCT03941860 · OUTCOME

To Compare the Change in Quantitative 18F-FDG PET/CT Parameters Over Time With the Addition of Ixazomib to Lenalidomide

Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial · Source last updated 2025-05-23

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Assessed at baseline and 1 year

What was measured

The difference in qPET parameters from the baseline 18FFDG PET/CT to the year 1 18F-FDG PET/CT will be reported by study arm. An analysis of covariance (ANCOVA) model will be used to test for a treatment effect on each qPET parameter, where the baseline qPET parameter value and an indicator for study arm are included as covariates, with the qPET parameter at year 1 as the model outcome.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denom Units Selected: Participants
description: The difference in qPET parameters from the baseline 18FFDG PET/CT to the year 1 18F-FDG PET/CT will be reported by study arm. An analysis of covariance (ANCOVA) model will be used to test for a treatment effect on each qPET parameter, where the baseline qPET parameter value and an indicator for study arm are included as covariates, with the qPET parameter at year 1 as the model outcome.
reporting Status: NOT_POSTED
time Frame: Assessed at baseline and 1 year
title: To Compare the Change in Quantitative 18F-FDG PET/CT Parameters Over Time With the Addition of Ixazomib to Lenalidomide
type: OTHER_PRE_SPECIFIED

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice